News
Is Aurinia Pharmaceuticals a Buy?
Where Will Aurinia Pharmaceuticals Be in 5 Years?
3 Charts That Show Why Aurinia Pharmaceuticals Stock Could Go Higher
3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now
An Exciting New Drug Is in Clinical Trials for Aspreva Pharmaceuticals
An Exciting New Drug Is in Clinical Trials for Aurinia Pharmaceuticals
Is Aurinia Pharmaceuticals' Management Its Best Asset?
Immunisierungsrate des VBI-eigenen Hepatitis B-Impfstoffs bei annähernd 100 %
Why Knight-Swift Transportation Stock Popped Today
Shares of Knight-Swift Transportation (NYSE: KNX) were moving higher today after the diversified transportation company topped analyst estimates in its third-quarter earnings report.
As of 11:27
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
Note revised call-in number for participants 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada)
The updated release reads:
AURINIA PHARMACEUTICALS TO RELEASE THIRD QUARTER FINANCIAL AND
Why Tilray Brands Stock Is Surging Today
Canada's Tilray Brands (NASDAQ: TLRY) is having a strong trading session today. Specifically, the consumer packaged goods and cannabis company's stock was up by 6.75% on heavy volume as of 1:31 p.m
1 Green Flag and 1 Red Flag for Tilray Stock
Canadian cannabis company Tilray Brands (NASDAQ: TLRY) has been on the right track ever since it merged with rival Aphria in 2021. From an operational standpoint, it had been consistently
Better Growth Stock: Tilray vs. Green Thumb Industries
Investing in the cannabis industry is tricky. Some investors may be tempted to entirely shun the space based on its performance over the last two years. However, a few companies still offer
Aphria: Wenn das Wörtchen 'Wenn' nicht wäre...
Aphria (WKN: A12HM0), das am 17. November sein "Annual Meeting of Shareholders" veranstalten wird, erfuhr zuletzt verstärkt Investoreninteresse. Das geht zurück auf das sogenannte "ATM"-Programm
Arbutus Biopharma: Kursexplosion dank positiver Studiendaten!
Zu den größten Gewinnern am US-Aktienmarkt zählt heute das Papier der kleinen US-amerikanischen Biotechcompany Arbutus Biopharma (WKN: A14XMD). Grund hierfür ist ein erster wichtiger
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will participate in one-on-one meetings with investors at the Leerink
Aurinia Announces 2024 Annual General Meeting Results
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024.
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued the following letter to shareholders in response to a letter from Lucien Selce.
Dear Fellow Shareholders:
Aurinia Provides Update on Proxy Statement
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) filed a supplement (the “Supplement”) to the Company’s Management Information and Proxy Statement dated June 3, 2024 (the “Proxy
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Jefferies Global Healthcare Conference in New York from June 4-6, 2024.
Aurinia
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024